Inhibition of CCR7 promotes NF-κB-dependent apoptosis and suppresses epithelial-mesenchymal transition in non-small cell lung cancer

Zhang,Lan; Xiao,Xuyang; An,Hui; Wang,Jian; Ma,Yanmei; Qian,Yi-Hua

doi:10.3892/or.2017.5524

Inhibition of CCR7 promotes NF-κB-dependent apoptosis and suppresses epithelial-mesenchymal transition in non-small cell lung cancer

Authors:
- Lan Zhang
- Xuyang Xiao
- Hui An
- Jian Wang
- Yanmei Ma
- Yi-Hua Qian
View Affiliations

Affiliations: School of Basic Medical Sciences, Health Science Center, Xi'an Jiaotong University, Xi'an, Shanxi 710061, P.R. China, Department of Thoracic Surgery, First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Cardiothoracic Surgery, First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Neurological Surgery, First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Nursing, First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Health Science Center, Xi'an Jiaotong University, Xi'an, Shanxi 710061, P.R. China
Published online on: March 23, 2017 https://doi.org/10.3892/or.2017.5524
Pages: 2913-2919

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activation of C-C chemokine receptor type 7 (CCR7) has been demonstrated to mediate the occurrence and progression of non-small cell lung cancer (NSCLC). However, the potential therapeutic role of CCR7 inhibition in NSCLC is still obscure. Thus, the present study was conducted to investigate the molecular mechanism underlying the inhibition of CCR7 on cell apoptosis and epithelial-mesenchymal transition (EMT) in NSCLC A549 cells. Chemokine ligand 21 (CCL21) was used to activate CCR7 and the results revealed that CCR7 upregulation inhibited cell apoptosis and affected apoptosis‑related protein levels. However, CCR7-siRNA treatment markedly promoted apoptosis and suppressed inflammatory response and transforming growth factor β1 (TGF-β1)-induced EMT. In addition, CCR7‑siRNA inactivated the NF-κB signaling pathway and inhibition of NF-κB via its specific antagonist, pyrrolidine dithiocarbamate, indicated that NF-κB was involved in the CCR7-mediated apoptosis. In conclusion, upregulation of CCR7 promoted cell proliferation and inflammation in A549 cells. In conclusion, inhibition of CCR7 via siRNA treatment promoted cell apoptosis and suppressed the inflammatory response and TGF-β1‑induced EMT, which may be associated with NF-κB signaling.

View Figures

View References

1	Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett. 362:208–217. 2015. View Article : Google Scholar : PubMed/NCBI
2	Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B and Tiseo M: Moving immune checkpoint blockade in thoracic tumors beyond non-small cell lung cancer. J Thorac Oncol. 11:1819–1836. 2016. View Article : Google Scholar : PubMed/NCBI
3	Naylor EC: Adjuvant therapy for stage I and II non-small cell lung cancer. Surg Oncol Clin N Am. 25:585–599. 2016. View Article : Google Scholar : PubMed/NCBI
4	Mburu YK, Wang J, Wood MA, Walker WH and Ferris RL: CCR7 mediates inflammation-associated tumor progression. Immunol Res. 36:61–72. 2006. View Article : Google Scholar : PubMed/NCBI
5	Worbs T and Förster R: A key role for CCR7 in establishing central and peripheral tolerance. Trends Immunol. 28:274–280. 2007. View Article : Google Scholar : PubMed/NCBI
6	Hong H, He C, Zhu S, Zhang Y, Wang X, She F and Chen Y: CCR7 mediates the TNF-α-induced lymphatic metastasis of gallbladder cancer through the ‘ERK1/2 - AP-1’ and ‘JNK - AP-1’ pathways. J Exp Clin Cancer Res. 35:512016. View Article : Google Scholar : PubMed/NCBI
7	Xu Y, Liu L, Qiu X, Liu Z, Li H, Li Z, Luo W and Wang E: CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. PLoS One. 7:e332622012. View Article : Google Scholar : PubMed/NCBI
8	Ma H, Gao L, Li S, Qin J, Chen L, Liu X, Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. Oncotarget. 6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V and Agelaki S: Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 13:R592011. View Article : Google Scholar : PubMed/NCBI
10	Tutunea-Fatan E, Majumder M, Xin X and Lala PK: The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis. Mol Cancer. 14:352015. View Article : Google Scholar : PubMed/NCBI
11	Zhang J, Zhou Y and Yang Y: CCR7 pathway induces epithelial-mesenchymal transition through up-regulation of Snail signaling in gastric cancer. Med Oncol. 32:4672015.PubMed/NCBI
12	Moschovakis GL and Förster R: Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur J Immunol. 42:1949–1955. 2012. View Article : Google Scholar : PubMed/NCBI
13	Saban DR: The chemokine receptor CCR7 expressed by dendritic cells: A key player in corneal and ocular surface inflammation. Ocul Surf. 12:87–99. 2014. View Article : Google Scholar : PubMed/NCBI
14	Cai W, Tao J, Zhang X, Tian X, Liu T, Feng X, Bai J, Yan C and Han Y: Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease. Arterioscler Thromb Vasc Biol. 34:1933–1941. 2014. View Article : Google Scholar : PubMed/NCBI
15	Mo M, Zhou M, Wang L, Qi L, Zhou K, Liu LF, Chen Z and Zu XB: CCL21/CCR7 enhances the proliferation, migration, and invasion of human bladder cancer T24 cells. PLoS One. 10:e01195062015. View Article : Google Scholar : PubMed/NCBI
16	Chi BJ, Du CL, Fu YF, Zhang YN and Wang RW: Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC. Int J Clin Exp Pathol. 8:12533–12540. 2015.PubMed/NCBI
17	Xu Y, Liu L, Qiu X, Jiang L, Huang B, Li H, Li Z, Luo W and Wang E: CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. PLoS One. 6:e211192011. View Article : Google Scholar : PubMed/NCBI
18	Sun L, Zhang Q, Li Y, Tang N and Qiu X: CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells. Int J Clin Exp Pathol. 8:15729–15738. 2015.PubMed/NCBI
19	Wang M, Jing Y, Hu L, Gao J, Ding L and Zhang J: Recent advances on the circadian gene PER2 and metabolic rhythm of lactation of mammary gland. Anim Nutr. 1:257–261. 2015.doi: 10.1016/j.aninu.2015.11.008. View Article : Google Scholar
20	Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M and Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol. 48:869–885. 2016.PubMed/NCBI
21	Jansen VM, Mayer IA and Arteaga CL: Is there a future for AKT inhibitors in the treatment of cancer? Clin Cancer Res. 22:2599–2601. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhang W, Tu G, Lv C, Long J, Cong L and Han Y: Matrix metalloproteinase-9 is up-regulated by CCL19/CCR7 interaction via PI3K/Akt pathway and is involved in CCL19-driven BMSCs migration. Biochem Biophys Res Commun. 451:222–228. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chuang CW, Pan MR, Hou MF and Hung WC: Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells. J Cell Physiol. 228:341–348. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kuwabara T, Tanaka Y, Ishikawa F, Kondo M, Sekiya H and Kakiuchi T: CCR7 ligands up-regulate IL-23 through PI3-kinase and NF-κB pathway in dendritic cells. J Leukoc Biol. 92:309–318. 2012. View Article : Google Scholar : PubMed/NCBI
25	Hollenbach M, Thonig A, Pohl S, Michel M, Ripoll C, Greinert RA, Michl P and Zipprich A: Inflammation and hypoxia regulate RAGE, NF-κB und pERK via glyoxalase I and methylglyoxal in sinusoidal endothelial cells: A possible mechanism in development of cirrhosis. Hepatology. 62:951a. 2015.
26	Zhao W, Sun Z, Wang S, Li Z and Zheng L: Wnt1 participates in inflammation induced by lipopolysaccharide through upregulating scavenger receptor A and NF-κB. Inflammation. 38:1700–1706. 2015. View Article : Google Scholar : PubMed/NCBI
27	Cupovic J, Gil-Cruz C, Onder L, Perez-Shibayama C, Chai Q and Ludewig B: Extra-lymphatic CCR7-ligand expression controls virus-induced CNS inflammation. Immunology. 140:35. 2013.
28	Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, Wu Y, Mei M, Zhang L and Wang X: Long non coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 5:159722015. View Article : Google Scholar : PubMed/NCBI
29	Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H, Meng Q, Pang H, Chen X, Liu Y, et al: USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer. 88:239–245. 2015. View Article : Google Scholar : PubMed/NCBI
30	Li F, Zou Z, Suo N, Zhang Z, Wan F, Zhong G, Qu Y, Ntaka KS and Tian H: CCL21/CCR7 axis activating chemotaxis accompanied with epithelial-mesenchymal transition in human breast carcinoma. Med Oncol. 31:1802014. View Article : Google Scholar : PubMed/NCBI